nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—CYP3A4—Everolimus—kidney cancer	0.124	0.293	CbGbCtD
Conivaptan—AVPR2—collecting duct of renal tubule—kidney cancer	0.108	0.465	CbGeAlD
Conivaptan—CYP3A4—Temsirolimus—kidney cancer	0.0837	0.198	CbGbCtD
Conivaptan—AVPR2—nephron—kidney cancer	0.0479	0.207	CbGeAlD
Conivaptan—CYP3A4—Pazopanib—kidney cancer	0.044	0.104	CbGbCtD
Conivaptan—AVPR2—urine—kidney cancer	0.0384	0.166	CbGeAlD
Conivaptan—CYP3A4—Erlotinib—kidney cancer	0.0314	0.0741	CbGbCtD
Conivaptan—CYP3A4—Paclitaxel—kidney cancer	0.0287	0.0678	CbGbCtD
Conivaptan—CYP3A4—Sorafenib—kidney cancer	0.0255	0.0603	CbGbCtD
Conivaptan—CYP3A4—Vinblastine—kidney cancer	0.0252	0.0595	CbGbCtD
Conivaptan—CYP3A4—Vincristine—kidney cancer	0.0248	0.0585	CbGbCtD
Conivaptan—CYP3A4—Sunitinib—kidney cancer	0.0207	0.0488	CbGbCtD
Conivaptan—CYP3A4—Doxorubicin—kidney cancer	0.0155	0.0366	CbGbCtD
Conivaptan—AVPR2—nephron tubule—kidney cancer	0.0103	0.0447	CbGeAlD
Conivaptan—AVPR2—renal system—kidney cancer	0.0094	0.0406	CbGeAlD
Conivaptan—AVPR2—kidney—kidney cancer	0.00909	0.0393	CbGeAlD
Conivaptan—CYP3A4—urine—kidney cancer	0.00585	0.0253	CbGeAlD
Conivaptan—Lomitapide—ABCB1—kidney cancer	0.00164	0.43	CrCbGaD
Conivaptan—Tolvaptan—ABCB1—kidney cancer	0.00146	0.383	CrCbGaD
Conivaptan—CYP3A4—renal system—kidney cancer	0.00143	0.00618	CbGeAlD
Conivaptan—CYP3A4—kidney—kidney cancer	0.00138	0.00598	CbGeAlD
Conivaptan—Atorvastatin—ABCB1—kidney cancer	0.000712	0.187	CrCbGaD
Conivaptan—Nervous system disorder—Everolimus—kidney cancer	0.00065	0.00193	CcSEcCtD
Conivaptan—Urethral disorder—Vincristine—kidney cancer	0.000646	0.00192	CcSEcCtD
Conivaptan—Skin disorder—Everolimus—kidney cancer	0.000644	0.00192	CcSEcCtD
Conivaptan—Erythema—Dactinomycin—kidney cancer	0.000642	0.00191	CcSEcCtD
Conivaptan—Cardiac failure—Capecitabine—kidney cancer	0.000636	0.00189	CcSEcCtD
Conivaptan—Infection—Erlotinib—kidney cancer	0.000635	0.00189	CcSEcCtD
Conivaptan—Pruritus—Temsirolimus—kidney cancer	0.00063	0.00188	CcSEcCtD
Conivaptan—Nervous system disorder—Erlotinib—kidney cancer	0.000627	0.00187	CcSEcCtD
Conivaptan—Anaemia—Sunitinib—kidney cancer	0.000627	0.00187	CcSEcCtD
Conivaptan—Hyponatraemia—Capecitabine—kidney cancer	0.000624	0.00186	CcSEcCtD
Conivaptan—Skin disorder—Erlotinib—kidney cancer	0.000621	0.00185	CcSEcCtD
Conivaptan—Hypotension—Everolimus—kidney cancer	0.000619	0.00184	CcSEcCtD
Conivaptan—Urinary tract disorder—Gemcitabine—kidney cancer	0.000618	0.00184	CcSEcCtD
Conivaptan—Oedema peripheral—Gemcitabine—kidney cancer	0.000616	0.00183	CcSEcCtD
Conivaptan—Urethral disorder—Gemcitabine—kidney cancer	0.000613	0.00182	CcSEcCtD
Conivaptan—Cardiac disorder—Vincristine—kidney cancer	0.000612	0.00182	CcSEcCtD
Conivaptan—Diarrhoea—Temsirolimus—kidney cancer	0.00061	0.00181	CcSEcCtD
Conivaptan—Hypertension—Sorafenib—kidney cancer	0.000609	0.00181	CcSEcCtD
Conivaptan—Pollakiuria—Paclitaxel—kidney cancer	0.000604	0.0018	CcSEcCtD
Conivaptan—Insomnia—Everolimus—kidney cancer	0.0006	0.00178	CcSEcCtD
Conivaptan—Angiopathy—Vincristine—kidney cancer	0.000598	0.00178	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000596	0.00177	CcSEcCtD
Conivaptan—Mediastinal disorder—Vincristine—kidney cancer	0.000594	0.00177	CcSEcCtD
Conivaptan—Pruritus—Pazopanib—kidney cancer	0.000594	0.00177	CcSEcCtD
Conivaptan—Anaemia—Dactinomycin—kidney cancer	0.000594	0.00177	CcSEcCtD
Conivaptan—Hyperglycaemia—Paclitaxel—kidney cancer	0.00059	0.00176	CcSEcCtD
Conivaptan—Dry mouth—Sorafenib—kidney cancer	0.000587	0.00175	CcSEcCtD
Conivaptan—Pneumonia—Paclitaxel—kidney cancer	0.000587	0.00175	CcSEcCtD
Conivaptan—Hypertension—Sunitinib—kidney cancer	0.000586	0.00174	CcSEcCtD
Conivaptan—Infestation NOS—Paclitaxel—kidney cancer	0.000583	0.00174	CcSEcCtD
Conivaptan—Infestation—Paclitaxel—kidney cancer	0.000583	0.00174	CcSEcCtD
Conivaptan—Cardiac disorder—Gemcitabine—kidney cancer	0.00058	0.00173	CcSEcCtD
Conivaptan—Insomnia—Erlotinib—kidney cancer	0.000578	0.00172	CcSEcCtD
Conivaptan—Dehydration—Capecitabine—kidney cancer	0.000578	0.00172	CcSEcCtD
Conivaptan—Mental disorder—Vincristine—kidney cancer	0.000577	0.00172	CcSEcCtD
Conivaptan—Diarrhoea—Pazopanib—kidney cancer	0.000574	0.00171	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000574	0.00171	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Everolimus—kidney cancer	0.000572	0.0017	CcSEcCtD
Conivaptan—Infection—Sorafenib—kidney cancer	0.000572	0.0017	CcSEcCtD
Conivaptan—Constipation—Vinblastine—kidney cancer	0.000569	0.00169	CcSEcCtD
Conivaptan—Pain—Vinblastine—kidney cancer	0.000569	0.00169	CcSEcCtD
Conivaptan—Angiopathy—Gemcitabine—kidney cancer	0.000567	0.00169	CcSEcCtD
Conivaptan—Orthostatic hypotension—Capecitabine—kidney cancer	0.000567	0.00169	CcSEcCtD
Conivaptan—Urinary tract infection—Paclitaxel—kidney cancer	0.000567	0.00169	CcSEcCtD
Conivaptan—Pain—Everolimus—kidney cancer	0.000567	0.00169	CcSEcCtD
Conivaptan—Constipation—Everolimus—kidney cancer	0.000567	0.00169	CcSEcCtD
Conivaptan—Vomiting—Temsirolimus—kidney cancer	0.000567	0.00169	CcSEcCtD
Conivaptan—Hypokalaemia—Capecitabine—kidney cancer	0.000565	0.00168	CcSEcCtD
Conivaptan—Dry mouth—Sunitinib—kidney cancer	0.000565	0.00168	CcSEcCtD
Conivaptan—Nervous system disorder—Sorafenib—kidney cancer	0.000564	0.00168	CcSEcCtD
Conivaptan—Mediastinal disorder—Gemcitabine—kidney cancer	0.000564	0.00168	CcSEcCtD
Conivaptan—Skin disorder—Sorafenib—kidney cancer	0.000559	0.00166	CcSEcCtD
Conivaptan—Headache—Temsirolimus—kidney cancer	0.000558	0.00166	CcSEcCtD
Conivaptan—Haematuria—Paclitaxel—kidney cancer	0.000556	0.00165	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000552	0.00164	CcSEcCtD
Conivaptan—Infection—Sunitinib—kidney cancer	0.00055	0.00164	CcSEcCtD
Conivaptan—Feeling abnormal—Vinblastine—kidney cancer	0.000548	0.00163	CcSEcCtD
Conivaptan—Constipation—Erlotinib—kidney cancer	0.000547	0.00163	CcSEcCtD
Conivaptan—Pain—Erlotinib—kidney cancer	0.000547	0.00163	CcSEcCtD
Conivaptan—Feeling abnormal—Everolimus—kidney cancer	0.000546	0.00163	CcSEcCtD
Conivaptan—Erythema—Gemcitabine—kidney cancer	0.000544	0.00162	CcSEcCtD
Conivaptan—Nervous system disorder—Sunitinib—kidney cancer	0.000543	0.00162	CcSEcCtD
Conivaptan—Skin disorder—Sunitinib—kidney cancer	0.000538	0.0016	CcSEcCtD
Conivaptan—Vomiting—Pazopanib—kidney cancer	0.000534	0.00159	CcSEcCtD
Conivaptan—Anaemia—Vincristine—kidney cancer	0.00053	0.00158	CcSEcCtD
Conivaptan—Nausea—Temsirolimus—kidney cancer	0.000529	0.00158	CcSEcCtD
Conivaptan—Candida infection—Doxorubicin—kidney cancer	0.000527	0.00157	CcSEcCtD
Conivaptan—Headache—Pazopanib—kidney cancer	0.000526	0.00157	CcSEcCtD
Conivaptan—Body temperature increased—Everolimus—kidney cancer	0.000524	0.00156	CcSEcCtD
Conivaptan—Infection—Dactinomycin—kidney cancer	0.000521	0.00155	CcSEcCtD
Conivaptan—Urinary tract disorder—Paclitaxel—kidney cancer	0.000517	0.00154	CcSEcCtD
Conivaptan—Oedema peripheral—Paclitaxel—kidney cancer	0.000516	0.00153	CcSEcCtD
Conivaptan—Urethral disorder—Paclitaxel—kidney cancer	0.000513	0.00153	CcSEcCtD
Conivaptan—Body temperature increased—Erlotinib—kidney cancer	0.000506	0.0015	CcSEcCtD
Conivaptan—Anaemia—Gemcitabine—kidney cancer	0.000503	0.0015	CcSEcCtD
Conivaptan—Insomnia—Sunitinib—kidney cancer	0.000501	0.00149	CcSEcCtD
Conivaptan—Nausea—Pazopanib—kidney cancer	0.000499	0.00148	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000497	0.00148	CcSEcCtD
Conivaptan—Hypertension—Vincristine—kidney cancer	0.000495	0.00147	CcSEcCtD
Conivaptan—Pain—Sorafenib—kidney cancer	0.000492	0.00146	CcSEcCtD
Conivaptan—Constipation—Sorafenib—kidney cancer	0.000492	0.00146	CcSEcCtD
Conivaptan—Cardiac disorder—Paclitaxel—kidney cancer	0.000486	0.00145	CcSEcCtD
Conivaptan—Hyperglycaemia—Capecitabine—kidney cancer	0.000484	0.00144	CcSEcCtD
Conivaptan—Pneumonia—Capecitabine—kidney cancer	0.000481	0.00143	CcSEcCtD
Conivaptan—Infestation—Capecitabine—kidney cancer	0.000479	0.00142	CcSEcCtD
Conivaptan—Infestation NOS—Capecitabine—kidney cancer	0.000479	0.00142	CcSEcCtD
Conivaptan—Sepsis—Doxorubicin—kidney cancer	0.000479	0.00142	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000478	0.00142	CcSEcCtD
Conivaptan—Angiopathy—Paclitaxel—kidney cancer	0.000475	0.00141	CcSEcCtD
Conivaptan—Constipation—Sunitinib—kidney cancer	0.000473	0.00141	CcSEcCtD
Conivaptan—Pain—Sunitinib—kidney cancer	0.000473	0.00141	CcSEcCtD
Conivaptan—Mediastinal disorder—Paclitaxel—kidney cancer	0.000472	0.0014	CcSEcCtD
Conivaptan—Hypertension—Gemcitabine—kidney cancer	0.00047	0.0014	CcSEcCtD
Conivaptan—Pruritus—Everolimus—kidney cancer	0.000469	0.0014	CcSEcCtD
Conivaptan—Infection—Vincristine—kidney cancer	0.000465	0.00138	CcSEcCtD
Conivaptan—Urinary tract infection—Capecitabine—kidney cancer	0.000465	0.00138	CcSEcCtD
Conivaptan—Phlebitis—Doxorubicin—kidney cancer	0.000465	0.00138	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00046	0.00137	CcSEcCtD
Conivaptan—Nervous system disorder—Vincristine—kidney cancer	0.000459	0.00137	CcSEcCtD
Conivaptan—Mental disorder—Paclitaxel—kidney cancer	0.000459	0.00136	CcSEcCtD
Conivaptan—Haematuria—Capecitabine—kidney cancer	0.000456	0.00136	CcSEcCtD
Conivaptan—Erythema—Paclitaxel—kidney cancer	0.000456	0.00136	CcSEcCtD
Conivaptan—Malnutrition—Paclitaxel—kidney cancer	0.000456	0.00136	CcSEcCtD
Conivaptan—Diarrhoea—Vinblastine—kidney cancer	0.000455	0.00135	CcSEcCtD
Conivaptan—Body temperature increased—Sorafenib—kidney cancer	0.000455	0.00135	CcSEcCtD
Conivaptan—Diarrhoea—Everolimus—kidney cancer	0.000454	0.00135	CcSEcCtD
Conivaptan—Pruritus—Erlotinib—kidney cancer	0.000453	0.00135	CcSEcCtD
Conivaptan—Pain—Dactinomycin—kidney cancer	0.000448	0.00133	CcSEcCtD
Conivaptan—Infection—Gemcitabine—kidney cancer	0.000441	0.00131	CcSEcCtD
Conivaptan—Body temperature increased—Sunitinib—kidney cancer	0.000438	0.0013	CcSEcCtD
Conivaptan—Diarrhoea—Erlotinib—kidney cancer	0.000438	0.0013	CcSEcCtD
Conivaptan—Hypotension—Vincristine—kidney cancer	0.000438	0.0013	CcSEcCtD
Conivaptan—Nervous system disorder—Gemcitabine—kidney cancer	0.000436	0.0013	CcSEcCtD
Conivaptan—Feeling abnormal—Dactinomycin—kidney cancer	0.000432	0.00129	CcSEcCtD
Conivaptan—Skin disorder—Gemcitabine—kidney cancer	0.000432	0.00128	CcSEcCtD
Conivaptan—Urinary tract disorder—Capecitabine—kidney cancer	0.000424	0.00126	CcSEcCtD
Conivaptan—Insomnia—Vincristine—kidney cancer	0.000424	0.00126	CcSEcCtD
Conivaptan—Oedema peripheral—Capecitabine—kidney cancer	0.000423	0.00126	CcSEcCtD
Conivaptan—Vomiting—Vinblastine—kidney cancer	0.000423	0.00126	CcSEcCtD
Conivaptan—Vomiting—Everolimus—kidney cancer	0.000421	0.00125	CcSEcCtD
Conivaptan—Anaemia—Paclitaxel—kidney cancer	0.000421	0.00125	CcSEcCtD
Conivaptan—Urethral disorder—Capecitabine—kidney cancer	0.000421	0.00125	CcSEcCtD
Conivaptan—Headache—Vinblastine—kidney cancer	0.000417	0.00124	CcSEcCtD
Conivaptan—Headache—Everolimus—kidney cancer	0.000415	0.00124	CcSEcCtD
Conivaptan—Hypotension—Gemcitabine—kidney cancer	0.000415	0.00124	CcSEcCtD
Conivaptan—Body temperature increased—Dactinomycin—kidney cancer	0.000414	0.00123	CcSEcCtD
Conivaptan—Hypoglycaemia—Doxorubicin—kidney cancer	0.00041	0.00122	CcSEcCtD
Conivaptan—Cardiac failure—Doxorubicin—kidney cancer	0.00041	0.00122	CcSEcCtD
Conivaptan—Pruritus—Sorafenib—kidney cancer	0.000407	0.00121	CcSEcCtD
Conivaptan—Vomiting—Erlotinib—kidney cancer	0.000407	0.00121	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Vincristine—kidney cancer	0.000404	0.0012	CcSEcCtD
Conivaptan—Hyponatraemia—Doxorubicin—kidney cancer	0.000402	0.0012	CcSEcCtD
Conivaptan—Insomnia—Gemcitabine—kidney cancer	0.000402	0.0012	CcSEcCtD
Conivaptan—Headache—Erlotinib—kidney cancer	0.000401	0.00119	CcSEcCtD
Conivaptan—Pain—Vincristine—kidney cancer	0.0004	0.00119	CcSEcCtD
Conivaptan—Constipation—Vincristine—kidney cancer	0.0004	0.00119	CcSEcCtD
Conivaptan—Cardiac disorder—Capecitabine—kidney cancer	0.000399	0.00119	CcSEcCtD
Conivaptan—Nausea—Vinblastine—kidney cancer	0.000395	0.00118	CcSEcCtD
Conivaptan—Nausea—Everolimus—kidney cancer	0.000394	0.00117	CcSEcCtD
Conivaptan—Diarrhoea—Sorafenib—kidney cancer	0.000394	0.00117	CcSEcCtD
Conivaptan—Hypertension—Paclitaxel—kidney cancer	0.000393	0.00117	CcSEcCtD
Conivaptan—Pruritus—Sunitinib—kidney cancer	0.000392	0.00117	CcSEcCtD
Conivaptan—Angiopathy—Capecitabine—kidney cancer	0.00039	0.00116	CcSEcCtD
Conivaptan—Mediastinal disorder—Capecitabine—kidney cancer	0.000387	0.00115	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000385	0.00115	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000384	0.00114	CcSEcCtD
Conivaptan—Pain—Gemcitabine—kidney cancer	0.00038	0.00113	CcSEcCtD
Conivaptan—Constipation—Gemcitabine—kidney cancer	0.00038	0.00113	CcSEcCtD
Conivaptan—Nausea—Erlotinib—kidney cancer	0.00038	0.00113	CcSEcCtD
Conivaptan—Dry mouth—Paclitaxel—kidney cancer	0.000379	0.00113	CcSEcCtD
Conivaptan—Diarrhoea—Sunitinib—kidney cancer	0.000379	0.00113	CcSEcCtD
Conivaptan—Mental disorder—Capecitabine—kidney cancer	0.000376	0.00112	CcSEcCtD
Conivaptan—Confusional state—Paclitaxel—kidney cancer	0.000375	0.00112	CcSEcCtD
Conivaptan—Malnutrition—Capecitabine—kidney cancer	0.000374	0.00111	CcSEcCtD
Conivaptan—Erythema—Capecitabine—kidney cancer	0.000374	0.00111	CcSEcCtD
Conivaptan—Dehydration—Doxorubicin—kidney cancer	0.000372	0.00111	CcSEcCtD
Conivaptan—Body temperature increased—Vincristine—kidney cancer	0.00037	0.0011	CcSEcCtD
Conivaptan—Infection—Paclitaxel—kidney cancer	0.00037	0.0011	CcSEcCtD
Conivaptan—Feeling abnormal—Gemcitabine—kidney cancer	0.000366	0.00109	CcSEcCtD
Conivaptan—Vomiting—Sorafenib—kidney cancer	0.000366	0.00109	CcSEcCtD
Conivaptan—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000366	0.00109	CcSEcCtD
Conivaptan—Nervous system disorder—Paclitaxel—kidney cancer	0.000365	0.00109	CcSEcCtD
Conivaptan—Hypokalaemia—Doxorubicin—kidney cancer	0.000364	0.00108	CcSEcCtD
Conivaptan—Skin disorder—Paclitaxel—kidney cancer	0.000361	0.00108	CcSEcCtD
Conivaptan—Headache—Sorafenib—kidney cancer	0.00036	0.00107	CcSEcCtD
Conivaptan—Diarrhoea—Dactinomycin—kidney cancer	0.000359	0.00107	CcSEcCtD
Conivaptan—Vomiting—Sunitinib—kidney cancer	0.000352	0.00105	CcSEcCtD
Conivaptan—Body temperature increased—Gemcitabine—kidney cancer	0.000351	0.00105	CcSEcCtD
Conivaptan—Hypotension—Paclitaxel—kidney cancer	0.000348	0.00103	CcSEcCtD
Conivaptan—Headache—Sunitinib—kidney cancer	0.000347	0.00103	CcSEcCtD
Conivaptan—Anaemia—Capecitabine—kidney cancer	0.000346	0.00103	CcSEcCtD
Conivaptan—Nausea—Sorafenib—kidney cancer	0.000342	0.00102	CcSEcCtD
Conivaptan—Insomnia—Paclitaxel—kidney cancer	0.000336	0.001	CcSEcCtD
Conivaptan—Vomiting—Dactinomycin—kidney cancer	0.000333	0.000992	CcSEcCtD
Conivaptan—Nausea—Sunitinib—kidney cancer	0.000329	0.000979	CcSEcCtD
Conivaptan—Hypertension—Capecitabine—kidney cancer	0.000323	0.000961	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000321	0.000956	CcSEcCtD
Conivaptan—Diarrhoea—Vincristine—kidney cancer	0.00032	0.000954	CcSEcCtD
Conivaptan—Pollakiuria—Doxorubicin—kidney cancer	0.00032	0.000951	CcSEcCtD
Conivaptan—Pain—Paclitaxel—kidney cancer	0.000318	0.000947	CcSEcCtD
Conivaptan—Constipation—Paclitaxel—kidney cancer	0.000318	0.000947	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000316	0.000941	CcSEcCtD
Conivaptan—Pruritus—Gemcitabine—kidney cancer	0.000314	0.000935	CcSEcCtD
Conivaptan—Hyperglycaemia—Doxorubicin—kidney cancer	0.000312	0.000929	CcSEcCtD
Conivaptan—Dry mouth—Capecitabine—kidney cancer	0.000311	0.000927	CcSEcCtD
Conivaptan—Nausea—Dactinomycin—kidney cancer	0.000311	0.000926	CcSEcCtD
Conivaptan—Pneumonia—Doxorubicin—kidney cancer	0.00031	0.000923	CcSEcCtD
Conivaptan—Infestation NOS—Doxorubicin—kidney cancer	0.000309	0.000918	CcSEcCtD
Conivaptan—Infestation—Doxorubicin—kidney cancer	0.000309	0.000918	CcSEcCtD
Conivaptan—Confusional state—Capecitabine—kidney cancer	0.000308	0.000916	CcSEcCtD
Conivaptan—Feeling abnormal—Paclitaxel—kidney cancer	0.000307	0.000912	CcSEcCtD
Conivaptan—Diarrhoea—Gemcitabine—kidney cancer	0.000304	0.000905	CcSEcCtD
Conivaptan—Infection—Capecitabine—kidney cancer	0.000303	0.000902	CcSEcCtD
Conivaptan—Urinary tract infection—Doxorubicin—kidney cancer	0.0003	0.000892	CcSEcCtD
Conivaptan—Nervous system disorder—Capecitabine—kidney cancer	0.000299	0.000891	CcSEcCtD
Conivaptan—Vomiting—Vincristine—kidney cancer	0.000298	0.000886	CcSEcCtD
Conivaptan—Skin disorder—Capecitabine—kidney cancer	0.000296	0.000882	CcSEcCtD
Conivaptan—Haematuria—Doxorubicin—kidney cancer	0.000294	0.000875	CcSEcCtD
Conivaptan—Body temperature increased—Paclitaxel—kidney cancer	0.000294	0.000875	CcSEcCtD
Conivaptan—Headache—Vincristine—kidney cancer	0.000293	0.000873	CcSEcCtD
Conivaptan—Hypotension—Capecitabine—kidney cancer	0.000285	0.000849	CcSEcCtD
Conivaptan—Vomiting—Gemcitabine—kidney cancer	0.000282	0.000841	CcSEcCtD
Conivaptan—Headache—Gemcitabine—kidney cancer	0.000278	0.000828	CcSEcCtD
Conivaptan—AVPR2—Arf6 trafficking events—CTNNA1—kidney cancer	0.000278	0.0527	CbGpPWpGaD
Conivaptan—Nausea—Vincristine—kidney cancer	0.000278	0.000828	CcSEcCtD
Conivaptan—Insomnia—Capecitabine—kidney cancer	0.000276	0.000822	CcSEcCtD
Conivaptan—Urinary tract disorder—Doxorubicin—kidney cancer	0.000274	0.000814	CcSEcCtD
Conivaptan—Oedema peripheral—Doxorubicin—kidney cancer	0.000273	0.000812	CcSEcCtD
Conivaptan—Urethral disorder—Doxorubicin—kidney cancer	0.000271	0.000808	CcSEcCtD
Conivaptan—Nausea—Gemcitabine—kidney cancer	0.000264	0.000785	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000264	0.000784	CcSEcCtD
Conivaptan—Pruritus—Paclitaxel—kidney cancer	0.000263	0.000783	CcSEcCtD
Conivaptan—Constipation—Capecitabine—kidney cancer	0.000261	0.000777	CcSEcCtD
Conivaptan—Pain—Capecitabine—kidney cancer	0.000261	0.000777	CcSEcCtD
Conivaptan—Cardiac disorder—Doxorubicin—kidney cancer	0.000257	0.000765	CcSEcCtD
Conivaptan—Diarrhoea—Paclitaxel—kidney cancer	0.000254	0.000757	CcSEcCtD
Conivaptan—Feeling abnormal—Capecitabine—kidney cancer	0.000252	0.000749	CcSEcCtD
Conivaptan—Angiopathy—Doxorubicin—kidney cancer	0.000251	0.000748	CcSEcCtD
Conivaptan—Mediastinal disorder—Doxorubicin—kidney cancer	0.00025	0.000743	CcSEcCtD
Conivaptan—Mental disorder—Doxorubicin—kidney cancer	0.000243	0.000722	CcSEcCtD
Conivaptan—Body temperature increased—Capecitabine—kidney cancer	0.000241	0.000718	CcSEcCtD
Conivaptan—Malnutrition—Doxorubicin—kidney cancer	0.000241	0.000717	CcSEcCtD
Conivaptan—Erythema—Doxorubicin—kidney cancer	0.000241	0.000717	CcSEcCtD
Conivaptan—Vomiting—Paclitaxel—kidney cancer	0.000236	0.000704	CcSEcCtD
Conivaptan—Headache—Paclitaxel—kidney cancer	0.000233	0.000693	CcSEcCtD
Conivaptan—Anaemia—Doxorubicin—kidney cancer	0.000223	0.000663	CcSEcCtD
Conivaptan—Nausea—Paclitaxel—kidney cancer	0.000221	0.000657	CcSEcCtD
Conivaptan—Pruritus—Capecitabine—kidney cancer	0.000216	0.000643	CcSEcCtD
Conivaptan—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000211	0.0398	CbGpPWpGaD
Conivaptan—Diarrhoea—Capecitabine—kidney cancer	0.000209	0.000621	CcSEcCtD
Conivaptan—Hypertension—Doxorubicin—kidney cancer	0.000208	0.000619	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000204	0.000607	CcSEcCtD
Conivaptan—Dry mouth—Doxorubicin—kidney cancer	0.000201	0.000597	CcSEcCtD
Conivaptan—Confusional state—Doxorubicin—kidney cancer	0.000198	0.00059	CcSEcCtD
Conivaptan—Infection—Doxorubicin—kidney cancer	0.000195	0.000582	CcSEcCtD
Conivaptan—Vomiting—Capecitabine—kidney cancer	0.000194	0.000578	CcSEcCtD
Conivaptan—Nervous system disorder—Doxorubicin—kidney cancer	0.000193	0.000574	CcSEcCtD
Conivaptan—Headache—Capecitabine—kidney cancer	0.000191	0.000569	CcSEcCtD
Conivaptan—Skin disorder—Doxorubicin—kidney cancer	0.000191	0.000569	CcSEcCtD
Conivaptan—Hypotension—Doxorubicin—kidney cancer	0.000184	0.000547	CcSEcCtD
Conivaptan—Nausea—Capecitabine—kidney cancer	0.000181	0.00054	CcSEcCtD
Conivaptan—Insomnia—Doxorubicin—kidney cancer	0.000178	0.00053	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.00017	0.000505	CcSEcCtD
Conivaptan—Pain—Doxorubicin—kidney cancer	0.000168	0.000501	CcSEcCtD
Conivaptan—Constipation—Doxorubicin—kidney cancer	0.000168	0.000501	CcSEcCtD
Conivaptan—Feeling abnormal—Doxorubicin—kidney cancer	0.000162	0.000482	CcSEcCtD
Conivaptan—Body temperature increased—Doxorubicin—kidney cancer	0.000156	0.000463	CcSEcCtD
Conivaptan—Pruritus—Doxorubicin—kidney cancer	0.000139	0.000414	CcSEcCtD
Conivaptan—Diarrhoea—Doxorubicin—kidney cancer	0.000135	0.000401	CcSEcCtD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000132	0.0251	CbGpPWpGaD
Conivaptan—Vomiting—Doxorubicin—kidney cancer	0.000125	0.000372	CcSEcCtD
Conivaptan—Headache—Doxorubicin—kidney cancer	0.000123	0.000367	CcSEcCtD
Conivaptan—AVPR2—Arf6 trafficking events—CDH1—kidney cancer	0.000122	0.0231	CbGpPWpGaD
Conivaptan—Nausea—Doxorubicin—kidney cancer	0.000117	0.000348	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000103	0.0195	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—ITPR2—kidney cancer	0.000102	0.0194	CbGpPWpGaD
Conivaptan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	9.6e-05	0.0182	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR2—kidney cancer	9.16e-05	0.0173	CbGpPWpGaD
Conivaptan—AVPR2—Arf6 trafficking events—CTNNB1—kidney cancer	8.99e-05	0.017	CbGpPWpGaD
Conivaptan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	8.89e-05	0.0168	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—ANXA1—kidney cancer	8.58e-05	0.0162	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—ANXA1—kidney cancer	8.47e-05	0.016	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—ANXA1—kidney cancer	8.41e-05	0.0159	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—OR4C13—kidney cancer	8.27e-05	0.0156	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—OR4C13—kidney cancer	8.21e-05	0.0155	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—kidney cancer	7.68e-05	0.0145	CbGpPWpGaD
Conivaptan—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	7.54e-05	0.0143	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—OR4C13—kidney cancer	7.51e-05	0.0142	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—OR4C13—kidney cancer	7.45e-05	0.0141	CbGpPWpGaD
Conivaptan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	7.44e-05	0.0141	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ATP7B—kidney cancer	5.91e-05	0.0112	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ANXA2—kidney cancer	5.91e-05	0.0112	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	5.91e-05	0.0112	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—POMC—kidney cancer	5.8e-05	0.011	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	5.69e-05	0.0108	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	5.68e-05	0.0108	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	5.64e-05	0.0107	CbGpPWpGaD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	4.86e-05	0.0092	CbGpPWpGaD
Conivaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	4.7e-05	0.00889	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	4.51e-05	0.00853	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—OR4C13—kidney cancer	4.43e-05	0.00839	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—OR4C13—kidney cancer	4.4e-05	0.00833	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—ANXA1—kidney cancer	4.33e-05	0.00819	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—ANXA1—kidney cancer	4.3e-05	0.00813	CbGpPWpGaD
Conivaptan—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	4.27e-05	0.00809	CbGpPWpGaD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—POMC—kidney cancer	4.15e-05	0.00786	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—POMC—kidney cancer	4.12e-05	0.0078	CbGpPWpGaD
Conivaptan—CYP3A4—Irinotecan Pathway—APC—kidney cancer	4.09e-05	0.00775	CbGpPWpGaD
Conivaptan—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	3.93e-05	0.00744	CbGpPWpGaD
Conivaptan—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	3.78e-05	0.00715	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LATS1—kidney cancer	3.77e-05	0.00714	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LATS1—kidney cancer	3.74e-05	0.00709	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	3.73e-05	0.00705	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—ACY1—kidney cancer	3.61e-05	0.00684	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—AKAP13—kidney cancer	3.43e-05	0.0065	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—AKAP13—kidney cancer	3.41e-05	0.00645	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AMER1—kidney cancer	3.21e-05	0.00607	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AMER1—kidney cancer	3.18e-05	0.00602	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—AKAP13—kidney cancer	3.12e-05	0.0059	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.11e-05	0.00589	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	3.1e-05	0.00587	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—AKAP13—kidney cancer	3.09e-05	0.00586	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.01e-05	0.00569	CbGpPWpGaD
Conivaptan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	2.93e-05	0.00555	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ITPR2—kidney cancer	2.92e-05	0.00552	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ITPR2—kidney cancer	2.9e-05	0.00548	CbGpPWpGaD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	2.79e-05	0.00528	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	2.78e-05	0.00527	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	2.76e-05	0.00523	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GPC3—kidney cancer	2.69e-05	0.00509	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CER1—kidney cancer	2.69e-05	0.00509	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GPC3—kidney cancer	2.67e-05	0.00505	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CER1—kidney cancer	2.67e-05	0.00505	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ITPR2—kidney cancer	2.65e-05	0.00502	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ITPR2—kidney cancer	2.63e-05	0.00498	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ANXA1—kidney cancer	2.45e-05	0.00463	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ANXA1—kidney cancer	2.43e-05	0.0046	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.37e-05	0.00449	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SFRP2—kidney cancer	2.28e-05	0.00432	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SFRP2—kidney cancer	2.27e-05	0.00429	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	2.23e-05	0.00423	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ANXA1—kidney cancer	2.22e-05	0.0042	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ANXA1—kidney cancer	2.21e-05	0.00417	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	2.13e-05	0.00402	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—POMC—kidney cancer	2.12e-05	0.00401	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—POMC—kidney cancer	2.11e-05	0.00398	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—PIK3CA—kidney cancer	2.06e-05	0.0039	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2.05e-05	0.00388	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	2.02e-05	0.00382	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	2.01e-05	0.0038	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	1.98e-05	0.00375	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	1.85e-05	0.00349	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—AKAP13—kidney cancer	1.84e-05	0.00349	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CASP2—kidney cancer	1.84e-05	0.00349	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CASP2—kidney cancer	1.83e-05	0.00346	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—AKAP13—kidney cancer	1.83e-05	0.00346	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GRB7—kidney cancer	1.68e-05	0.00319	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GRB7—kidney cancer	1.67e-05	0.00316	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	1.63e-05	0.00309	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	1.61e-05	0.00305	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ITPR2—kidney cancer	1.57e-05	0.00296	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ITPR2—kidney cancer	1.55e-05	0.00294	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CTNNA1—kidney cancer	1.42e-05	0.00269	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HSPB1—kidney cancer	1.41e-05	0.00267	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—EIF4EBP1—kidney cancer	1.41e-05	0.00267	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CTNNA1—kidney cancer	1.41e-05	0.00267	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—EIF4EBP1—kidney cancer	1.4e-05	0.00265	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HSPB1—kidney cancer	1.4e-05	0.00265	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—RAF1—kidney cancer	1.34e-05	0.00254	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.32e-05	0.0025	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ANXA1—kidney cancer	1.31e-05	0.00248	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TSC1—kidney cancer	1.31e-05	0.00248	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSMD7—kidney cancer	1.31e-05	0.00248	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ANXA1—kidney cancer	1.3e-05	0.00247	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSMD7—kidney cancer	1.3e-05	0.00247	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TSC1—kidney cancer	1.3e-05	0.00247	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FLT1—kidney cancer	1.27e-05	0.00241	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FLT1—kidney cancer	1.26e-05	0.00239	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.22e-05	0.0023	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—POMC—kidney cancer	1.2e-05	0.00227	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—POMC—kidney cancer	1.19e-05	0.00225	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—JUNB—kidney cancer	1.18e-05	0.00223	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PAK1—kidney cancer	1.18e-05	0.00223	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—JUNB—kidney cancer	1.17e-05	0.00221	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PAK1—kidney cancer	1.17e-05	0.00221	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.16e-05	0.0022	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—PTGS1—kidney cancer	1.09e-05	0.00206	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—POMC—kidney cancer	1.09e-05	0.00206	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—POMC—kidney cancer	1.08e-05	0.00204	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.86e-06	0.00187	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF2—kidney cancer	9.63e-06	0.00182	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN2B—kidney cancer	9.59e-06	0.00181	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF2—kidney cancer	9.56e-06	0.00181	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN2B—kidney cancer	9.52e-06	0.0018	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF1R—kidney cancer	9.31e-06	0.00176	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF1R—kidney cancer	9.24e-06	0.00175	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—RAF1—kidney cancer	8.97e-06	0.0017	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—RAF1—kidney cancer	8.91e-06	0.00169	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—IL2—kidney cancer	8.86e-06	0.00168	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—IL2—kidney cancer	8.79e-06	0.00166	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTP1—kidney cancer	8.06e-06	0.00153	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL2—kidney cancer	8.04e-06	0.00152	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL2—kidney cancer	7.99e-06	0.00151	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	7.95e-06	0.00151	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HIF1A—kidney cancer	7.67e-06	0.00145	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TSC2—kidney cancer	7.65e-06	0.00145	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HIF1A—kidney cancer	7.61e-06	0.00144	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TSC2—kidney cancer	7.59e-06	0.00144	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—GSTM1—kidney cancer	7.41e-06	0.0014	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KDR—kidney cancer	7.33e-06	0.00139	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	7.31e-06	0.00138	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KDR—kidney cancer	7.28e-06	0.00138	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	7.02e-06	0.00133	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	6.93e-06	0.00131	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KIT—kidney cancer	6.75e-06	0.00128	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—APC—kidney cancer	6.75e-06	0.00128	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—APC—kidney cancer	6.7e-06	0.00127	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KIT—kidney cancer	6.7e-06	0.00127	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—MAPK3—kidney cancer	6.47e-06	0.00122	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—POMC—kidney cancer	6.43e-06	0.00122	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—MAPK3—kidney cancer	6.42e-06	0.00122	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—POMC—kidney cancer	6.38e-06	0.00121	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—BRAF—kidney cancer	6.35e-06	0.0012	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—BRAF—kidney cancer	6.3e-06	0.00119	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ACY1—kidney cancer	6.18e-06	0.00117	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—MAPK1—kidney cancer	6.15e-06	0.00116	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—MAPK1—kidney cancer	6.11e-06	0.00116	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PIK3CA—kidney cancer	5.88e-06	0.00111	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PIK3CA—kidney cancer	5.84e-06	0.0011	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—KRAS—kidney cancer	5.81e-06	0.0011	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—KRAS—kidney cancer	5.77e-06	0.00109	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PIK3CA—kidney cancer	5.34e-06	0.00101	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PIK3CA—kidney cancer	5.3e-06	0.001	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RAF1—kidney cancer	5.3e-06	0.001	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RELA—kidney cancer	5.28e-06	0.000999	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RAF1—kidney cancer	5.26e-06	0.000996	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PDHB—kidney cancer	5.25e-06	0.000994	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ERBB2—kidney cancer	5.24e-06	0.000992	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RELA—kidney cancer	5.24e-06	0.000992	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—POMC—kidney cancer	5.24e-06	0.000991	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ERBB2—kidney cancer	5.21e-06	0.000985	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MTOR—kidney cancer	5.17e-06	0.000979	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MTOR—kidney cancer	5.14e-06	0.000972	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CCBL1—kidney cancer	4.94e-06	0.000935	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CDKN1B—kidney cancer	4.86e-06	0.000919	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CDKN1B—kidney cancer	4.82e-06	0.000912	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL2—kidney cancer	4.75e-06	0.000899	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL2—kidney cancer	4.72e-06	0.000893	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CCND1—kidney cancer	4.63e-06	0.000877	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—JUN—kidney cancer	4.62e-06	0.000875	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CCND1—kidney cancer	4.6e-06	0.000871	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—JUN—kidney cancer	4.59e-06	0.000869	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CTNNB1—kidney cancer	4.59e-06	0.000868	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CTNNB1—kidney cancer	4.55e-06	0.000862	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTEN—kidney cancer	4.47e-06	0.000846	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTEN—kidney cancer	4.44e-06	0.00084	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GLIPR1—kidney cancer	4.28e-06	0.000811	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PPAT—kidney cancer	4.28e-06	0.000811	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—VEGFA—kidney cancer	4.04e-06	0.000764	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—VEGFA—kidney cancer	4.01e-06	0.000759	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—APRT—kidney cancer	3.98e-06	0.000754	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—FH—kidney cancer	3.98e-06	0.000754	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK3—kidney cancer	3.82e-06	0.000723	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK3—kidney cancer	3.79e-06	0.000718	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GPC3—kidney cancer	3.74e-06	0.000709	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MYC—kidney cancer	3.72e-06	0.000703	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MYC—kidney cancer	3.69e-06	0.000698	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CA2—kidney cancer	3.64e-06	0.000689	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MAPK1—kidney cancer	3.64e-06	0.000688	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MAPK1—kidney cancer	3.61e-06	0.000683	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALAD—kidney cancer	3.55e-06	0.000672	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ST3GAL2—kidney cancer	3.46e-06	0.000656	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KRAS—kidney cancer	3.43e-06	0.00065	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KRAS—kidney cancer	3.41e-06	0.000645	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ALDH1A1—kidney cancer	3.39e-06	0.000641	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PGK1—kidney cancer	3.25e-06	0.000614	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC5A3—kidney cancer	3.25e-06	0.000614	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—LDHB—kidney cancer	3.18e-06	0.000602	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PIK3CA—kidney cancer	3.15e-06	0.000597	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PIK3CA—kidney cancer	3.13e-06	0.000593	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—kidney cancer	3.05e-06	0.000578	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—kidney cancer	3.03e-06	0.000573	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CA9—kidney cancer	2.76e-06	0.000522	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CRABP1—kidney cancer	2.35e-06	0.000444	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ITPR2—kidney cancer	2.18e-06	0.000413	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTT1—kidney cancer	1.99e-06	0.000377	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ACHE—kidney cancer	1.99e-06	0.000377	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SCARB1—kidney cancer	1.88e-06	0.000356	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS1—kidney cancer	1.86e-06	0.000353	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSMD7—kidney cancer	1.83e-06	0.000346	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—BCHE—kidney cancer	1.73e-06	0.000328	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.71e-06	0.000324	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.65e-06	0.000313	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTP1—kidney cancer	1.38e-06	0.000261	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ABCB1—kidney cancer	1.31e-06	0.000247	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GSTM1—kidney cancer	1.27e-06	0.00024	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.2e-06	0.000227	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—POMC—kidney cancer	8.96e-07	0.00017	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS2—kidney cancer	7.14e-07	0.000135	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTEN—kidney cancer	6.23e-07	0.000118	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PIK3CA—kidney cancer	4.4e-07	8.32e-05	CbGpPWpGaD
